scholarly journals Effect of combined glucocorticoid therapy on bronchial asthma dynamics

2022 ◽  
Vol 50 (1) ◽  
pp. 68-74
Author(s):  
Ekaterina Batrakova ◽  
Oxana Kartashova ◽  
Liudmila Babaskina ◽  
Olga Pashanova
Keyword(s):  
Bronchial Asthma ◽  
Flow Rate ◽  
Asthma Exacerbation ◽  
Peak Flow ◽  
Clinical Manifestations ◽  
Peak Flow Rate ◽  
Output Rate ◽  
Breath Rate ◽  
Group 2 ◽  
Group 1

This work is aimed to compare the effectiveness of parenteral and inhalation bronchial asthma treatment in combination with glucocorticosteroids and bronchodilators. The study was conducted in 2020 in Botkin City Clinical Hospital (Moscow, the Russian Federation). Case histories of 106 patients diagnosed with bronchial asthma exacerbation of moderate severity were analyzed. Patients were divided into two equal groups based on the therapy method: (1) Group 1 received systemic glucocorticosteroids parenterally in combination with inhalation glucocorticosteroids; (2) Group 2 received systemic glucocorticosteroids parenterally, but inhalation therapy was performed with a nebulizer. Clinical manifestations of bronchial asthma have been recorded. During hospital admission, the breath rate was 22.0 for Group 1 and 21.5 for Group 2, P ≥ 0.05, and heart rates were 93.0 and 92.5, respectively (P ≥ 0.05). All indices (blood saturation, breath rate, peak output rate) in Group 1 remained unchanged 4 h after the start of the therapy, while in Group 2, peak flow rate changed to 53.5% with a median increase of 72.0 ml over 4 h, P ≤ 0.05. On Day 3, patients of Group 1 demonstrated a peak flow rate of 59.5%, P ≤ 0.05, and on Day 10, patients of Group 2 had a peak output rate of 53.0 and 59.5%, respectively (P ≤ 0.05). Systemic glucocorticoids were eliminated in 47 patients of Group 1 and in all patients of Group 2. The treatment tactics applied in Group 2 resulted in faster and more significant improvement in patients diagnosed with bronchial asthma exacerbation. Both treatment regimens showed high results.

scholarly journals Milk flow-controlled changes of pulsation ratio and pulsation rate affect milking characteristics in dairy cows

2009 ◽  
Vol 76 (3) ◽  
pp. 272-277 ◽  
Author(s):  
Sarah Ambord ◽  
Rupert M Bruckmaier
Keyword(s):  
Flow Rate ◽  
Peak Flow ◽  
Phase Changes ◽  
Peak Flow Rate ◽  
Milk Ejection ◽  
Milk Flow ◽  
Group 3 ◽  
Group 2 ◽  
Pulsation Cycle ◽  
Group 1

To test a system with milk flow-controlled pulsation, milk flow was recorded in 29 Holstein cows during machine milking. The three different treatments were routine milking (including a pre-stimulation of 50–70 s), milking with a minimum of teat preparation and milking with milk flow-controlled b-phase, i.e. with a gradually elongated b-phase of the pulsation cycle with increasing milk flow rate and shortening again during decreasing milk flow. For data evaluation the herd was divided into three groups based on the peak flow rate at routine milking (group 1: <3·2 kg/min; group 2: 3·2–4·5 kg/min; group 3: >4·5 kg/min). Compared with routine milking, milking with milk flow-controlled b-phase caused a significant elevation of the peak flow rate and the duration of incline lasted longer especially in cows with a peak flow rate of >3·2 kg/min in routine milking. In milking with a minimum of teat preparation the duration of incline lasted longer compared with the two other treatments. Bimodality of milk flow, i.e. delayed milk ejection at the start of milking, was most frequent at milking with a minimum of teat preparation. No significant differences between routine milking and milking with milk flow-controlled b-phase were detected for all other milking characteristics. In summary, milking with milk flow-controlled b-phase changes the course of milk removal, however mainly in cows with high peak flow rates.

scholarly journals Correlation of intravesical prostatic protrusion with severity of lower urinary symptoms among patients with benign prostatic hyperplasia

2021 ◽  
Vol 27 (1) ◽  
Author(s):  
Babatunde K. Hamza ◽  
Muhammed Ahmed ◽  
Ahmad Bello ◽  
Musliu Adetola Tolani ◽  
Mudi Awaisu ◽  
...  
Keyword(s):  
Flow Rate ◽  
Bladder Outlet Obstruction ◽  
Peak Flow ◽  
Prostate Volume ◽  
Outlet Obstruction ◽  
Peak Flow Rate ◽  
The Mean ◽  
Benign Prostate ◽  
Intravesical Prostatic Protrusion ◽  
Lower Urinary

Abstract Background Benign prostate hyperplasia (BPH) is characterized by an increase in the number of epithelial and stromal cells in the periurethral area of the prostate. Lower urinary tract symptoms (LUTS) often develop as a manifestation of bladder outlet obstruction (BOO) due to benign prostate enlargement. When the prostate enlarges, protrusion into the bladder often occurs as a result of morphological changes of the gland. Prostatic protrusion into the bladder can be measured with ultrasound as intravesical prostatic protrusion (IPP). There are studies that have shown IPP as a reliable predictor of bladder obstruction index (BOOI) as measured by pressure flow studies. IPP is thereby reliable in assessing the severity of BOO in patients with BPH. The severity of symptoms in patients with BPH can be assessed through several scoring systems. The most widely used symptoms scoring system is the International Prostate Symptoms Score (IPSS). The aim of this study is to determine the correlation of IPP with IPSS in men with BPH at our facility. Methods The study was a cross-sectional observational study that was conducted at the Division of Urology, Department of Surgery, in our facility. The study was conducted on patients greater than 50 years LUTS and an enlarged prostate on digital rectal examination and/or ultrasound. All consenting patients were assessed with the International Prostate Symptoms Score (IPSS) questionnaire, following which an abdominal ultrasound was done to measure the intravesical prostatic protrusion (IPP), prostate volume (PV) and post-void residual (PVR) urine. All the patients had uroflowmetry, and the peak flow rate was determined. The data obtained were entered into a proforma. The results were analyzed using Statistical Package for Social Sciences (SPSS) software package version 20. Results A total of 167 patients were seen during the study period. The mean age was 63.7 ± 8.9 years, with a range of 45–90 years. The mean IPSS was 18.24 ± 6.93, with a range of 5–35. There were severe symptoms in 49.1%, while 43.1% had moderate symptoms and 7.8% had mild symptoms. The overall mean IPP was 10.3 ± 8 mm. Sixty-two patients (37.1%) had grade I IPP, 21 patients (12.6%) had grade II IPP and 84 patients (50.3%) had grade III IPP. The mean prostate volume and peak flow rate were 64 g ± 34.7 and 11.6 ml/s ± 5.4, respectively. The median PVR was 45 ml with a range of 0–400 ml. There was a significant positive correlation between the IPP and IPSS (P = 0.001). IPP also had a significant positive correlation with prostate volume and post-void residual and a significant negative correlation with the peak flow rate (P < 0.01). Conclusion Intravesical prostatic protrusion is a reliable predictor of severity of LUTS as measured by IPSS, and it also shows good correlation with other surrogates of bladder outlet obstruction.

scholarly journals The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial

2021 ◽  
Vol 30 ◽  
pp. 096368972110249
Author(s):  
G Adas ◽  
Z Cukurova ◽  
K Kart Yasar ◽  
R Yilmaz ◽  
N Isiksacan ◽  
...  
Keyword(s):  
Growth Factors ◽  
Critically Ill ◽  
Inflammatory Cytokines ◽  
Clinical Manifestations ◽  
Systematic Effect ◽  
Cytokine Storm ◽  
Group 3 ◽  
Anti Inflammatory ◽  
Group 2 ◽  
Group 1

The aim of this clinical trial was to control the cytokine storm by administering mesenchymal stem cells (MSCs) to critically-ill COVID-19 patients, to evaluate the healing effect, and to systematically investigate how the treatment works. Patients with moderate and critical COVID-19 clinical manifestations were separated as Group 1 (moderate cases, n = 10, treated conventionally), Group 2 (critical cases, n = 10, treated conventionally), and Group 3 (critical cases, n = 10, treated conventionally plus MSCs transplantation therapy of three consecutive doses on treatment days 0, 3, and 6, (as 3 × 106 cells/kg, intravenously). The treatment mechanism of action was investigated with evaluation markers of the cytokine storm, via biochemical parameters, levels of proinflammatory and anti-inflammatory cytokines, analyses of tissue regeneration via the levels of growth factors, apoptosis markers, chemokines, matrix metalloproteinases, and granzyme-B, and by the assessment of the immunomodulatory effects via total oxidant/antioxidant status markers and the levels of lymphocyte subsets. In the assessment of the overall mortality rates of all the cases, six patients in Group-2 and three patients in Group-3 died, and there was no loss in Group-1. Proinflammatory cytokines IFNγ, IL-6, IL-17A, IL-2, IL-12, anti-inflammatory cytokines IL-10, IL-13, IL-1ra, and growth factors TGF-β, VEGF, KGF, and NGF levels were found to be significant in Group-3. When Group-2 and Group-3 were compared, serum ferritin, fibrinogen and CRP levels in Group-3 had significantly decreased. CD45 +, CD3 +, CD4 +, CD8 +, CD19 +, HLA-DR +, and CD16 + / CD56 + levels were evaluated. In the statistical comparison of the groups, significance was only determined in respect of neutrophils. The results demonstrated the positive systematic and cellular effects of MSCs application on critically ill COVID-19 patients in a versatile way. This effect plays an important role in curing and reducing mortality in critically ill patients.

Decreasing peak flow rate with a new bag-valve-mask device: effects on respiratory mechanics, and gas distribution in a bench model of an unprotected airway

Resuscitation ◽  
2003 ◽  
Vol 57 (2) ◽  
pp. 193-199 ◽  
Author(s):  
Horst G. Wagner-Berger ◽  
Volker Wenzel ◽  
Angelika Stallinger ◽  
Wolfgang G. Voelckel ◽  
Klaus Rheinberger ◽  
...  
Keyword(s):  
Flow Rate ◽  
Respiratory Mechanics ◽  
Peak Flow ◽  
Peak Flow Rate ◽  
Gas Distribution ◽  
Unprotected Airway ◽  
Bench Model

scholarly journals The role of the new coronavirus infection (COVID-19) in the progression and development of cerebrovascular diseases. A competent choice of pathogenic treatment is the key to success in treatment and prevention. An expert’s view from the ‘red zone’

2021 ◽  
Vol 13 (1) ◽  
pp. 57-66
Author(s):  
V. V. Kovalchuk
Keyword(s):  
Emotional Disorders ◽  
Clinical Manifestations ◽  
Cerebrovascular Diseases ◽  
Recent Experience ◽  
Treatment And Prevention ◽  
State Recovery ◽  
Group 2 ◽  
State Examination ◽  
Group 1

COVID-19 worsens the course of cerebrovascular diseases (CVD), including chronic cerebral ischaemia (CCI). The Actovegin drug, which has long been widely used in CCI treatment, has an antioxidant and endothelium protective effect. It makes sense to study the effect of Actovegin therapy on the clinical manifestations of CCI in patients with a recent experience of COVID-19.Objective: to evaluate Actovegin efficacy in the treatment of CCI in patients with a recent experience of COVID-19.Patients and methods. The study included 440 patients (234 female; 206 male) with a recent experience of COVID-19, suffering from CCI, their average age being 67.8 years (from 54 to 85 years). All patients were broken down into two groups of 220 people (the patients in Group 1 were administrated Actovegin, the ones in Group 2 – were not). All patients were followed up for 90 days; their condition was assessed by the severity of clinical manifestations of CCI, using special scales and questionnaires.Results and discussion. After 90 days of follow-up, the frequency of complaints of cognitive impairment, sleep disorder, dizziness, fatigue, emotional disorders, and headache in Group 1 was significantly lower than in Group 2 (p<0.05). According to Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), Multidimensional Fatigue Inventory (MFI-20), and Spiegel Sleep Questionnaire (SSQ), the average indicators improved significantly more in Group 1 than in Group 2 (p<0.05). The absence of quality of life impairment and their minimal severity were observed in Group 1 in 77.9%; in Group 2 – in 33.7% (p<0.001). Statistically significant differences between the groups of patients were also observed in relation to emotional state recovery according to the Wakefield Questionnaire and the Spielberger State Trait Anxiety inventory.Conclusion. The observational study demonstrated the efficacy of Actovegin in the treatment of main clinical manifestations of CCI in patients with recent COVID-19 experience.

A Method of Measuring the Peak Flow-Rate and the Regurgitant Volume of Regurgitation

1990 ◽  
pp. 125-129
Author(s):  
Motoaki Sugawara ◽  
Akio Hirai ◽  
Yasutsugu Seo ◽  
Yasuo Miyajima ◽  
Takanobu Uchibori
Keyword(s):  
Flow Rate ◽  
Peak Flow ◽  
Peak Flow Rate ◽  
Regurgitant Volume

Effect of magnesium loading on magnesium delivery to the juxtamedullary end-descending limb

1985 ◽  
Vol 248 (1) ◽  
pp. F145-F151
Author(s):  
D. R. Roy
Keyword(s):  
Flow Rate ◽  
Magnesium Concentration ◽  
Group 4 ◽  
Intravenous Magnesium ◽  
Group 3 ◽  
Group 2 ◽  
Magnesium Excretion ◽  
Plasma Magnesium ◽  
Normal Controls ◽  
Group 1

Previous micropuncture and microperfusion studies in acutely hypermagnesemic rats have yielded conflicting results with respect to magnesium transport in Henle's loop. The following experiments were performed to reexamine, by micropuncture of papillary end-descending limb, whether magnesium undergoes intratubular secretion in magnesium-loaded rats. Group 1 animals served as normal controls; group 2 animals received an acute intravenous magnesium load; group 3 animals were orally magnesium loaded for 3 wk before receiving an acute intravenous magnesium load during micropuncture; group 4 animals were acutely thyroparathyroidectomized and water loaded before receiving an acute magnesium load. Fractional magnesium delivery to the end-descending limb did not differ from the corresponding value observed in the superficial proximal tubule in normal animals (67 +/- 5.3 vs. 76 +/- 7.6%). Acute magnesium loading raised plasma magnesium concentration and fractional magnesium excretion more than twofold but did not change fractional magnesium delivery to the end-descending limb or superficial nephron significantly from control values (75 and 73%). Chronic oral magnesium loading raised daily urinary magnesium excretion threefold (183 vs. 53 mumol X day-1 X 100 g body wt-1, P less than 0.05), but acute magnesium loading in this group did not significantly alter fractional delivery to the end-descending limb (85 +/- 10%, NS). Increasing intratubular flow rate while acutely raising plasma magnesium concentration (group 4) also did not induce intratubular magnesium secretion. The absence of significant changes in fractional magnesium delivery to the end-descending limb during magnesium loading suggests that intratubular magnesium secretion, if at all present, is very small and of questionable significance.

scholarly journals Peak flow rate records in surveys: reproducibility of observers' reports.

Thorax ◽  
1984 ◽  
Vol 39 (11) ◽  
pp. 828-832 ◽  
Author(s):  
K M Venables ◽  
P S Burge ◽  
A G Davison ◽  
A J Newman Taylor
Keyword(s):  
Flow Rate ◽  
Peak Flow ◽  
Peak Flow Rate
Sign in / Sign up

Export Citation Format

Share Document